E 聯邦制藥國際控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 3933) e = P- 告 载 F B 讓 生 命 更 有 價 值 目錄 目錄 | --- | --- | --- | |-------|-------|--------------------------| | | 2 | 2022 年度大事記 | | | 4 | 公司資料 | | | 5 | 財務概要 | | | 6 | 主席報告 | | | 10 | 管理層討論與分析 | | | 20 | 董事及高級管理層履歷 | | | 24 | 董事會報告 | | | 31 | 企業管治報告 | | | 38 | 獨立核數師報告 | | | 43 | 綜合損益及其他全面收益表 | | | 45 | 綜合財務狀況表 | | | 47 | 綜合權益變動表 | | | 48 | 綜合現金流量表 | | | 50 | 綜合財務報表附註 | | | 158 | 財務摘要 | 2021 年度大事記 年度 2022 大事記 | --- | --- | --- | |-------|-------|--------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 (於開曼群島成立之有限公司) (股份代號: 3933) 二零二二年全年業績公告 財務摘要 | --- | --- | --- | --- | |-----------------------------------------|-----------------------|----------------------|-------------| | | 二零二二年 | 二零二一年 | 上升 | | | 人民幣千元 | 人民幣千元 | % | | 收入 未計利息、稅項、折舊及攤銷前溢利 | 11,334,262 2,640,792 | 9,703,438 1,883,735 | 16.8% 40.2% | | 除稅前溢利 | 2,006,766 | 1,202,647 ...

Financial Performance - Revenue for the year 2021 reached RMB 9,703,438 thousand, representing a 10.6% increase from RMB 8,772,488 thousand in 2020[8] - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was RMB 1,883,735 thousand, up 12.3% from RMB 1,678,072 thousand in the previous year[8] - Profit before tax increased by 36.3% to RMB 1,202,647 thousand, compared to RMB 882,334 thousand in 2020[8] - Net profit attributable to shareholders was RMB 988,098 thousand, a 40.6% rise from RMB 702,989 thousand in 2020[8] - Basic and diluted earnings per share increased by 34.9% to RMB 53.7 cents, up from RMB 39.81 cents in the previous year[8] - The company reported a total comprehensive income of RMB 990,060 thousand for the year, compared to RMB 706,822 thousand in 2020, marking an increase of 40.1%[106] - The company reported a profit attributable to owners of the company of RMB 702,989,000 for the year, up from RMB 700,918,000 in the previous year[111] - The company’s total equity attributable to owners increased to RMB 9,340,492,000 as of December 31, 2021, from RMB 8,613,906,000 at the end of 2020, reflecting a growth of approximately 8.4%[111] Dividends and Shareholder Returns - The board proposed a final dividend of RMB 0.08 per share and a special dividend of RMB 0.02 per share, totaling an annual dividend of RMB 0.14 per share[12] - The company recognized dividends payable of RMB 128,140,000 for the year, compared to RMB 220,847,000 in the previous year, showing a decrease of approximately 41.9%[111] - The company paid dividends totaling RMB 220,847 thousand in 2021, which is an increase from RMB 128,140 thousand in 2020, indicating a commitment to returning value to shareholders[116] Research and Development - The company plans to enhance investment in new drug research and development, aiming to strengthen its scientific capabilities and expand its talent pool[12] - Research and development expenses for the year were RMB 465,200,000, a 37.0% increase, with 23 new products currently under development[18] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development efforts[45] Market Position and Strategy - The company aims to leverage its comprehensive competitive advantages in drug research, production, and sales to strengthen its market position amid intense competition[12] - The company anticipates continued growth in the upcoming year, driven by new product launches and market expansion strategies[190] - Future outlook includes potential mergers and acquisitions to strengthen market position and diversify offerings[200] Operational Efficiency - Financial costs decreased significantly from RMB 181,300,000 in 2020 to RMB 60,200,000 in 2021, a reduction of 66.8%[20] - The company reported a significant increase in deposits in pledged bank accounts, totaling RMB (2,551,448) thousand in 2021, compared to RMB (1,735,053) thousand in 2020[116] - The company has established treasury policies to monitor and manage currency exchange risks associated with its operations[24] Governance and Compliance - The company has adopted corporate governance practices in line with the Hong Kong Stock Exchange's requirements[68] - The board consists of six executive directors and three independent non-executive directors, with established committees for audit, remuneration, nomination, and risk management[70] - The company has maintained compliance with applicable laws and regulations without any significant violations affecting its operations[65] Assets and Liabilities - The total assets of the group as of December 31, 2021, were approximately RMB 16,331,100,000, compared to RMB 14,963,700,000 in 2020[23] - Total liabilities increased to approximately RMB 6,991,200,000 as of December 31, 2021, from RMB 6,351,900,000 in 2020[23] - The group’s cash and bank balances, net of bank borrowings and trade payables, amounted to RMB 212,600,000 as of December 31, 2021, up from RMB 20,300,000 in 2020[23] Financial Reporting and Standards - The company has adopted revised Hong Kong Financial Reporting Standards, which may impact future financial reporting but did not have a significant effect on the current year's financial statements[126] - The company recognizes revenue when control of the related goods or services is transferred to the customer, with contract liabilities recorded for amounts received from customers for which goods or services have yet to be delivered[142] - The company assesses control over subsidiaries based on the ability to exercise power, receive variable returns, and influence those returns, with consolidated financial statements reflecting the results from the date control is obtained[139] Credit Risk Management - The company assesses the expected credit loss based on the difference between the cash flows due and the expected cash flows to be received[179] - The expected credit loss for trade receivables is assessed based on historical credit loss experience and adjusted for forward-looking factors, with a specific focus on the nature and industry of the debtors[185] - The company will write off financial assets when there is evidence of severe financial distress and no realistic prospect of recovery, such as bankruptcy[176]

目錄 | 2019年大事記 | 2 | | --- | --- | | 公司資料 | 4 | | 財務概要 | 5 | | 主席報告 | 6 | | 管理層討論與分析 | 10 | | 董事及高級管理層履歷 | 18 | | 董事會報告 | 22 | | 企業管治報告 | 29 | | 獨立核數師報告 | 36 | | 綜合損益及其他全面收益表 | 41 | | 綜合財務狀況表 | 42 | | 綜合權益變動表 | 44 | | 綜合現金流量表 | 46 | | 綜合財務報表附註 | 48 | | 財務摘要 | 160 | 目錄 年 2019 大事記 1月 • 聯邦制藥榮膺「2018金港股最具價值醫藥及醫療股公司」。 2月 • 聯邦制藥榮獲「2018年度珠海市醫藥科技創新先進單位」。 3月 • 聯邦制藥蟬聯「中國西藥原料行業會員企業出口十強」。 • 內蒙古聯邦動保通過「高新技術企業」認證。 • 「雙優行動－基層糖尿病防治管理培訓班」項目於河南鄭州順利啟動。 4月 • 由中國藥學會科技發展中心主辦、聯邦制藥協辦「2019醫療衛生機構改革形勢下的醫院藥學變革 與發展高端論壇」在廣東珠海成功舉辦。 • 聯邦制藥臨床 ...